These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16495012)

  • 1. Bias from industry trial funding? A framework, a suggested approach, and a negative result.
    Barden J; Derry S; McQuay HJ; Moore AR
    Pain; 2006 Apr; 121(3):207-218. PubMed ID: 16495012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling industry bias in clinical trials.
    Gluud LL
    Pain; 2006 Apr; 121(3):175-176. PubMed ID: 16513277
    [No Abstract]   [Full Text] [Related]  

  • 3. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.
    Pang WK; Yeter KC; Torralba KD; Spencer HJ; Khan NA
    Int J Rheum Dis; 2015 Jul; 18(6):606-15. PubMed ID: 26012523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sponsorship bias in the comparative efficacy of psychotherapy and pharmacotherapy for adult depression: meta-analysis.
    Cristea IA; Gentili C; Pietrini P; Cuijpers P
    Br J Psychiatry; 2017 Jan; 210(1):16-23. PubMed ID: 27810891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.
    Perlis RH; Perlis CS; Wu Y; Hwang C; Joseph M; Nierenberg AA
    Am J Psychiatry; 2005 Oct; 162(10):1957-60. PubMed ID: 16199844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study.
    Turner K; Carboni-Jiménez A; Benea C; Elder K; Levis B; Boruff J; Roseman M; Bero L; Lexchin J; Turner EH; Benedetti A; Thombs BD
    BMJ Open; 2020 May; 10(5):e035633. PubMed ID: 32398334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. If the Facts Were Not Untruths, Their Implications Were: Sponsorship Bias and Misleading Communication.
    Steel D
    Kennedy Inst Ethics J; 2018; 28(2):119-144. PubMed ID: 30100597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
    Als-Nielsen B; Chen W; Gluud C; Kjaergard LL
    JAMA; 2003 Aug; 290(7):921-8. PubMed ID: 12928469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
    Bero L; Oostvogel F; Bacchetti P; Lee K
    PLoS Med; 2007 Jun; 4(6):e184. PubMed ID: 17550302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry Collaboration and Primary Guest Authorship of High-Impact Randomized Clinical Trials: A Cross-Sectional Study.
    Roper N; Korenstein D
    J Gen Intern Med; 2015 Oct; 30(10):1421-5. PubMed ID: 25832619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
    Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
    JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sponsors' participation in conduct and reporting of industry trials: a descriptive study.
    Lundh A; Krogsbøll LT; Gøtzsche PC
    Trials; 2012 Aug; 13():146. PubMed ID: 22920226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conflict of interest, round 2.
    Freedman R; Lewis DA; Michels R; Pine DS; Schultz SK; Tamminga C; Patterson SL; McIntyre JS; Goldman HH; Yudofsky SC; Hales RE; Rapaport MH; Hales D; Krajeski J; Kupfer DJ; Badaracco MA; Scully JH
    Am J Psychiatry; 2006 Sep; 163(9):1481-3. PubMed ID: 16946167
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes.
    Nkansah N; Nguyen T; Iraninezhad H; Bero L
    Public Health Nutr; 2009 Oct; 12(10):1931-7. PubMed ID: 19254426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family physicians support Open Pharma.
    Glauser W
    CMAJ; 2017 Jul; 189(27):E923. PubMed ID: 28694317
    [No Abstract]   [Full Text] [Related]  

  • 18. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study.
    Clifford TJ; Barrowman NJ; Moher D
    BMC Health Serv Res; 2002 Sep; 2(1):18. PubMed ID: 12213183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conflicts of interest and outcomes of clinical trials of antidepressants: An 18-year retrospective study.
    Waqas A; Baig AA; Khalid MA; Aedma KK; Naveed S
    J Psychiatr Res; 2019 Sep; 116():83-87. PubMed ID: 31212249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disclosure of financial competing interests in randomised controlled trials: cross sectional review.
    Gross CP; Gupta AR; Krumholz HM
    BMJ; 2003 Mar; 326(7388):526-7. PubMed ID: 12623910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.